Literature DB >> 23820871

Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line.

Douglas D Fang1, Joan Cao, Jitesh P Jani, Konstantinos Tsaparikos, Alessandra Blasina, Jill Kornmann, Maruja E Lira, Jianying Wang, Zuzana Jirout, Justin Bingham, Zhou Zhu, Yin Gu, Gerrit Los, Zdenek Hostomsky, Todd Vanarsdale.   

Abstract

Evaluating the effects of novel drugs on appropriate tumor models has become crucial for developing more effective therapies that target highly tumorigenic and drug-resistant cancer stem cell (CSC) populations. In this study, we demonstrate that a subset of cancer cells with CSC properties may be enriched into tumor spheroids under stem cell conditions from a non-small cell lung cancer cell line. Treating these CSC-like cells with gemcitabine alone and a combination of gemcitabine and the novel CHK1 inhibitor PF-00477736 revealed that PF-00477736 enhances the anti-proliferative effect of gemcitabine against both the parental and the CSC-like cell populations. However, the CSC-like cells exhibited resistance to gemcitabine-induced apoptosis. Collectively, the spheroid-forming CSC-like cells may serve as a model system for understanding the mechanism underlying the drug resistance of CSCs and for guiding the development of better therapies that can inhibit tumor growth and eradicate CSCs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23820871     DOI: 10.1007/s11684-013-0270-6

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  36 in total

1.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

Authors:  Michael F Clarke; John E Dick; Peter B Dirks; Connie J Eaves; Catriona H M Jamieson; D Leanne Jones; Jane Visvader; Irving L Weissman; Geoffrey M Wahl
Journal:  Cancer Res       Date:  2006-09-21       Impact factor: 12.701

2.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.

Authors:  Dario Ponti; Aurora Costa; Nadia Zaffaroni; Graziella Pratesi; Giovanna Petrangolini; Danila Coradini; Silvana Pilotti; Marco A Pierotti; Maria Grazia Daidone
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

3.  Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic.

Authors:  Lubna Patrawala; Tammy Calhoun; Robin Schneider-Broussard; Jianjun Zhou; Kent Claypool; Dean G Tang
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

4.  A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.

Authors:  Antonio Jimeno; Georg Feldmann; Ana Suárez-Gauthier; Zeshaan Rasheed; Anna Solomon; Gang-Ming Zou; Belen Rubio-Viqueira; Elena García-García; Fernando López-Ríos; William Matsui; Anirban Maitra; Manuel Hidalgo
Journal:  Mol Cancer Ther       Date:  2009-01-27       Impact factor: 6.261

Review 5.  Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.

Authors:  Z Fishelson; N Donin; S Zell; S Schultz; M Kirschfink
Journal:  Mol Immunol       Date:  2003-09       Impact factor: 4.407

6.  Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer.

Authors:  Arkadiusz Z Dudek; Krzysztof Lesniewski-Kmak; Timothy Larson; Konstantin Dragnev; Rachel Isaksson; Vinita Gupta; Michael A Maddaus; Robert A Kratzke
Journal:  J Thorac Oncol       Date:  2009-08       Impact factor: 15.609

7.  Identification and characterization of ovarian cancer-initiating cells from primary human tumors.

Authors:  Shu Zhang; Curt Balch; Michael W Chan; Hung-Cheng Lai; Daniela Matei; Jeanne M Schilder; Pearlly S Yan; Tim H-M Huang; Kenneth P Nephew
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

8.  Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4.

Authors:  Matilde Todaro; Mileidys Perez Alea; Anna B Di Stefano; Patrizia Cammareri; Louis Vermeulen; Flora Iovino; Claudio Tripodo; Antonio Russo; Gaspare Gulotta; Jan Paul Medema; Giorgio Stassi
Journal:  Cell Stem Cell       Date:  2007-10-11       Impact factor: 24.633

9.  Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.

Authors:  Alessandra Blasina; Jill Hallin; Enhong Chen; Maria Elena Arango; Eugenia Kraynov; James Register; Stephan Grant; Sacha Ninkovic; Ping Chen; Tim Nichols; Patrick O'Connor; Kenna Anderes
Journal:  Mol Cancer Ther       Date:  2008-08       Impact factor: 6.261

10.  The malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer.

Authors:  Saroj K Basak; Mysore S Veena; Scott Oh; Ge Huang; Eri Srivatsan; Min Huang; Sherven Sharma; Raj K Batra
Journal:  PLoS One       Date:  2009-06-12       Impact factor: 3.240

View more
  6 in total

1.  Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.

Authors:  Tri Nguyen; Elisa Hawkins; Akhil Kolluri; Maciej Kmieciak; Haeseong Park; Hui Lin; Steven Grant
Journal:  Leuk Res       Date:  2014-11-11       Impact factor: 3.156

Review 2.  ATR/CHK1 inhibitors and cancer therapy.

Authors:  Zhaojun Qiu; Nancy L Oleinick; Junran Zhang
Journal:  Radiother Oncol       Date:  2017-10-18       Impact factor: 6.280

Review 3.  ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells.

Authors:  Cyril Ronco; Anthony R Martin; Luc Demange; Rachid Benhida
Journal:  Medchemcomm       Date:  2016-11-30       Impact factor: 3.597

4.  Targeting lung cancer through inhibition of checkpoint kinases.

Authors:  Randi G Syljuåsen; Grete Hasvold; Sissel Hauge; Åslaug Helland
Journal:  Front Genet       Date:  2015-02-27       Impact factor: 4.599

5.  Ca2+ signalling plays a role in celastrol-mediated suppression of synovial fibroblasts of rheumatoid arthritis patients and experimental arthritis in rats.

Authors:  Vincent Kam Wai Wong; Congling Qiu; Su-Wei Xu; Betty Yuen Kwan Law; Wu Zeng; Hui Wang; Francesco Michelangeli; Ivo Ricardo De Seabra Rodrigues Dias; Yuan Qing Qu; Tsz Wai Chan; Yu Han; Ni Zhang; Simon Wing Fai Mok; Xi Chen; Lu Yu; Hudan Pan; Sami Hamdoun; Thomas Efferth; Wen Jing Yu; Wei Zhang; Zheng Li; Yuesheng Xie; Riqiang Luo; Quan Jiang; Liang Liu
Journal:  Br J Pharmacol       Date:  2019-07-04       Impact factor: 8.739

6.  CD44-Targeted Magnetic Nanoparticles Kill Head And Neck Squamous Cell Carcinoma Stem Cells In An Alternating Magnetic Field.

Authors:  Zhennan Gao; Xuxia Wang; Zhan Su; Duanqin Liu; Liying Chen; Jun Zhang; Lu Ru; Zhiyu Chen
Journal:  Int J Nanomedicine       Date:  2019-09-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.